Valuation dashboard for Immutep Limited (IMMP) with P/E N/A, P/B 1.03, EV/EBITDA -0.26 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.
Analysis Summary
Immutep Limited reported revenue of $14.2M in the most recent fiscal year, growing at a 5-year CAGR of 29.8%.
Trailing-twelve-month margins: gross margin 85.0%, operating margin -6.0%, net margin -5.4%.
At the current price of $0.33, IMMP has negative trailing earnings (P/E not meaningful) and an ROE of -126.06%. Market capitalisation stands at $48M.
Balance sheet quality for IMMP: current ratio of 5.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.03 |
| EV / EBITDA | -0.26 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-1.52 |
| vs Current Price | -565.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IMMP | Immutep Limited | $48M | 1.03 | -126.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.33 |
| Market Cap | $48M |
| Exchange | NASDAQ |
| Country | AU |
Profitability
| Return on Equity | -126.06% |
| Return on Invested Capital | -118.22% |
| Return on Assets | -93.15% |
| Gross Margin | 84.97% |
| Operating Margin | -597.44% |
| Net Margin | -544.79% |
Related companies: ACHV · ALLO · CABA · CADL · CAPR · EDIT · MREO
Explore sector: Healthcare · Biotechnology
More sections of IMMP: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks